Hla-Hla Thein1, Edwin Khoo2, Michael A Campitelli2, Ahmad Zaheen3, Qilong Yi4, Prithwish De5, C C Earle6. 1. Dalla Lana School of Public Health, University of Toronto, Toronto, Ont. ; Ontario Institute for Cancer Research/Cancer Care Ontario, Toronto, Ont. ; Institute for Clinical Evaluative Sciences, Toronto, Ont. 2. Dalla Lana School of Public Health, University of Toronto, Toronto, Ont. 3. Faculty of Medicine, University of Toronto, Toronto, Ont. 4. National Epidemiology and Surveillance, Canadian Blood Services, Ottawa, Ont. 5. Canadian Cancer Society, Toronto, Ont. ; Dalla Lana School of Public Health, University of Toronto, Toronto, Ont. 6. Ontario Institute for Cancer Research/Cancer Care Ontario, Toronto, Ont. ; Institute for Clinical Evaluative Sciences, Toronto, Ont.
Abstract
BACKGROUND: The incidence of hepatocellular carcinoma (HCC) is increasing and survival rates are poor. Our objectives were to estimate the relative survival over time in patients with HCC in Ontario and to examine potential factors associated with excess mortality risk. METHODS: We performed a population-based retrospective cohort analysis involving patients with a diagnosis of HCC in Ontario between 1990 and 2009 using data extracted from the Ontario Cancer Registry. Relative survival was estimated by controlling for background mortality using expected mortality from Ontario life tables. A generalized linear model was used to estimate the excess mortality risk for important factors. RESULTS: A total of 5645 patients had HCC diagnosed during the study period; 4412 (78.2%) of these patients were male. Improvements in 1-year relative survival were observed across all age groups over time: the highest was among those patients less than 60 years of age who had a diagnosis of HCC during 2005-2009, with 1-year survival exceeding 50% for both sexes. However, the overall 5-year relative survival did not exceed 28%. The excess mortality risk decreased with increased years of follow-up, recent diagnosis, and curative or noncurative treatments for HCC, whereas excess mortality risk increased with age. INTERPRETATION: Although improving, the prognosis for HCC remains poor. Our findings highlight the importance of effective prevention and treatment for HCC to reduce the burden of disease and improve health care systems.
BACKGROUND: The incidence of hepatocellular carcinoma (HCC) is increasing and survival rates are poor. Our objectives were to estimate the relative survival over time in patients with HCC in Ontario and to examine potential factors associated with excess mortality risk. METHODS: We performed a population-based retrospective cohort analysis involving patients with a diagnosis of HCC in Ontario between 1990 and 2009 using data extracted from the Ontario Cancer Registry. Relative survival was estimated by controlling for background mortality using expected mortality from Ontario life tables. A generalized linear model was used to estimate the excess mortality risk for important factors. RESULTS: A total of 5645 patients had HCC diagnosed during the study period; 4412 (78.2%) of these patients were male. Improvements in 1-year relative survival were observed across all age groups over time: the highest was among those patients less than 60 years of age who had a diagnosis of HCC during 2005-2009, with 1-year survival exceeding 50% for both sexes. However, the overall 5-year relative survival did not exceed 28%. The excess mortality risk decreased with increased years of follow-up, recent diagnosis, and curative or noncurative treatments for HCC, whereas excess mortality risk increased with age. INTERPRETATION: Although improving, the prognosis for HCC remains poor. Our findings highlight the importance of effective prevention and treatment for HCC to reduce the burden of disease and improve health care systems.
Authors: Goodarz Danaei; Stephen Vander Hoorn; Alan D Lopez; Christopher J L Murray; Majid Ezzati Journal: Lancet Date: 2005-11-19 Impact factor: 79.321
Authors: Claudia Allemani; Hannah K Weir; Helena Carreira; Rhea Harewood; Devon Spika; Xiao-Si Wang; Finian Bannon; Jane V Ahn; Christopher J Johnson; Audrey Bonaventure; Rafael Marcos-Gragera; Charles Stiller; Gulnar Azevedo e Silva; Wan-Qing Chen; Olufemi J Ogunbiyi; Bernard Rachet; Matthew J Soeberg; Hui You; Tomohiro Matsuda; Magdalena Bielska-Lasota; Hans Storm; Thomas C Tucker; Michel P Coleman Journal: Lancet Date: 2014-11-26 Impact factor: 79.321
Authors: Nathaniel Jembere; Michael A Campitelli; Morris Sherman; Jordan J Feld; Wendy Lou; Stuart Peacock; Eric Yoshida; Murray D Krahn; Craig Earle; Hla-Hla Thein Journal: PLoS One Date: 2012-07-13 Impact factor: 3.240
Authors: Adam C Winters; Julie C Sung; Brooke Wyatt; Deeva Berera; Thomas D Schiano; Myron E Schwartz; Ponni V Perumalswami; Andrea D Branch Journal: Clin Liver Dis (Hoboken) Date: 2018-11-06
Authors: Hla-Hla Thein; Michael A Campitelli; Latifa T Yeung; Ahmad Zaheen; Eric M Yoshida; Craig C Earle Journal: PLoS One Date: 2015-09-23 Impact factor: 3.240
Authors: Hong Y Pan; Qing Q Wu; Qiao Q Yin; Yi N Dai; Yi C Huang; Wei Zheng; Tian C Hui; Mei J Chen; Ming S Wang; Jia J Zhang; Hai J Huang; Yong X Tong Journal: ACS Omega Date: 2021-01-04